tyrosyl-arginyl-phenylalanyl-lysinamide has been researched along with beta-funaltrexamine in 1 studies
| Studies (tyrosyl-arginyl-phenylalanyl-lysinamide) | Trials (tyrosyl-arginyl-phenylalanyl-lysinamide) | Recent Studies (post-2010) (tyrosyl-arginyl-phenylalanyl-lysinamide) | Studies (beta-funaltrexamine) | Trials (beta-funaltrexamine) | Recent Studies (post-2010) (beta-funaltrexamine) |
|---|---|---|---|---|---|
| 74 | 0 | 17 | 542 | 1 | 54 |
| Protein | Taxonomy | tyrosyl-arginyl-phenylalanyl-lysinamide (IC50) | beta-funaltrexamine (IC50) |
|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.082 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.082 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.082 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.082 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.082 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Neilan, CL; Nguyen, TM; Pasternak, GW; Schiller, PW | 1 |
1 other study(ies) available for tyrosyl-arginyl-phenylalanyl-lysinamide and beta-funaltrexamine
| Article | Year |
|---|---|
Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide.
Topics: Analgesics; Animals; Drug Tolerance; Humans; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Oligodeoxyribonucleotides, Antisense; Oligopeptides; Opioid Peptides; Pain Measurement; Receptors, Opioid, mu; Time Factors | 2001 |